

CLAIMS

1. A therapeutic agent for a keratoconjunctival disorder comprising

5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenylmethyl]thiazolidine-2,4-dione,

N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine or a salt thereof as an active ingredient.

2. The therapeutic agent according to Claim 1, wherein the keratoconjunctival disorder is dry eyes, corneal ulcer, keratitis, conjunctivitis, superficial punctate keratopathy, corneal epithelial defects, conjunctive epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis and filamentary keratitis.

3. The therapeutic agent according to Claim 1, which is in a dosage form of an eye drop or an ophthalmic ointment.

4. A method for treating a keratoconjunctival disorder comprising administering to a patient a therapeutically effective amount of

5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenylmethyl]thiazolidine-2,4-dione,

N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl

-4-oxazolyl)ethoxy]phenyl)methyl]glycine or a salt thereof.

5. The therapeutic method according to Claim 4, wherein the keratoconjunctival disorder is dry eyes, corneal ulcer, keratitis, conjunctivitis, superficial punctate keratopathy, corneal epithelial defects, conjunctive epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis and filamentary keratitis.

6. The therapeutic method according to Claim 4, wherein the administration is instillation of an eye drop or administration of an ophthalmic ointment.

7. A use of

5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenylmethyl]thiazolidine-2,4-dione,
N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]glycine or a salt thereof
for manufacturing a therapeutic agent for a keratoconjunctival disorder.

8. The use according to Claim 7, wherein the keratoconjunctival disorder is dry eyes, corneal ulcer, keratitis, conjunctivitis, superficial punctate keratopathy, corneal epithelial defects, conjunctive epithelial defects,

keratoconjunctivitis sicca, superior limbic
keratoconjunctivitis and filamentary keratitis.

9. The use according to Claim 7, wherein the therapeutic agent is in a dosage form of an eye drop or an ophthalmic ointment.